Reduction of C-reactive protein and the use of anti-hypertensives

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 975-983

  Savoia, Carmine ^a   Schiffrin, Ernesto L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

ARBs; Hypertension; Vascular inflammation

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; IRBESARTAN; LOSARTAN; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INFLAMMATION; MEDITERRANEAN DIET; MONOTHERAPY; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; WEIGHT REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; HYPERTENSION; INFLAMMATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 38149098447     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Agabiti Rosei E, Morelli P, Rizzoni D. 2005b. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press, 1:14-22.
2. Agabiti Rosei E, Rizzoni D, Muiesan ML, et al. 2005a. CENTRO (CandEsartaN on aTherosclerotic Risk factOrs) study investigators. Effects on candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin dependent diabetes mellitus. J Hypertens, 23:435-44.
3. Albert MA, Danielson E, Rifai N, Ridker PM. 2001. Effect of statin therapy on C-reactive protein levels: the pravastatin Inflammation/CRP Evaluation (PRINCE), a randomized trial and cohort study. J Am Med Assoc, 286:64-70.
4. Andersen S, Schalkwijk CG, Stehouwer CD, Parving HH. 2000. Angiotensin II blockade is associated with decreased leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care, 23:1031-2.
5. Arnand IS, Latini R, Florea VG, et al. 2005. C-reactive protein in heart failure prognostic value and the effect of valsartan. Circulation, 112:1428-34.
6. Barzilay JI, Peterson D, Cushman M, et al. 2004. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis, 44:25-34.
7. Blake JG, Ridker PM. 2001. Novel clinical markers of vascular wall inflammation. Circ Res, 89:763-71.
8. Blake GJ, Rifai N, Buring JE, Ridker PM. 2003. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation, 108:2993-9.
9. Brull DJ, Sanders J, Rumley A, et al. 2002. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart, 87:252-5.
10. Chae CU, Lee RT, Rifai N, Ridker PM. 2001. Blood pressure and inflammation in apparently healthy men. Hypertension, 38:399-403.
11. Chobanian AV, Bakris GL, Black HR, et al. 2003. National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. Hypertension, 42:1206-52.
12. Chrysohoou C, Pitsavos C, Panagiotakos DB, et al. 2004. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens, 17:568-73.
13. De Ciuceis C, Amiri F, Brassard P, et al. 2005. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioseler Thromb Vasc Biol, 25:2106-13.
14. Devaraj S, Xu DJ, Jialal I. 2003. C-Reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implication for the metabolic syndrome and atherothrombosis. Circulation, 107:398-404.
15. Engstrom G, Janzon L, Berglund G, et al. 2002. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma protein. Arterioscler Thromb Vasc Biol, 22:2054-8.
16. Esposito K, Marfella R, Ciotola M, et al. 2004. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. J Am Med Assoc, 292:1440-6.
17. Fiedel BA, Gewurz H. 1976. Effects of C-reactive protein on platelet function, II: inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen. J Immunol, 117:1073-8.
18. Fliser D, Buchholz K, Haller H. 2004. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation, 110:1103-7.
19. Galis ZS, Sukhova GK, Lark MW, et al. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 94:2494-503.
20. Gasic S, Wagner OF, Fasching P, et al. 1999. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens, 12:217-22.
21. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. 2000. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol, 20:2175-83.
22. Guba M, Steinhauer M, Buchner M, et al. 2000. Differential effect of short term ace- and AT1 -receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock, 13:190-6.
23. Hattori Y, Matsumura M, Kasai K. 2003. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res, 58:186-95.
24. Hernandez-Presa M, Bustos C, Ortego M, et al. 1997. Angiotensin convertine enzyme inhibition prevents arterial nuclear factor kappa B activation monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation, 95:1532-41.
25. Heuertz RM, Webster RO. 1997. Role of C-reactive protein in acute lung injury. Mol Med Today, 3:539-45.
26. Jilma B, Li-Saw-Hee FL, Wagner OF, et al. 2002. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci (Lond), 103:131-6.
27. Joynt KE, Gattis WA, Hasselblad V, et al. 2004. Effect of angiotensin converting enzyme inhibitors, beta blockers statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol, 93:783-5.
28. Jung O, Marklund SL, Geiger H, et al. 2003. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res, 93:622-9.
29. Kalinina N, Agrotis A, Tararak E, et al. 2002. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 22:2037-43.
30. Khreiss T, Jozsef L, Hossain S, et al. 2002. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem, 277:40775-81.
31. Khreiss T, Jozsef L, Potempa LA, Filep JG. 2004a. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation, 109:2016-22.
32. Khreiss T, Jozsef L, Potempa LA, Filep JG. 2004b. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation, 110:2713-20.
33. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. 1999. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 19:1623-1629.
34. Koh KK, Ahn JY, Han SH, et al. 2003. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol, 42:905-910.
35. Koh KK, Han SH, Chung WJ, et al. 2004. Comparison of effect of losartan, irbesartan, and candesartan, on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol, 93:1432-35.
36. Koh KK, Han SH, Quon MJ, Ahn JY, Shin EK. 2005a. Beneficial effect of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care, 28:1419-24.
37. Koh KK, Han SH, Quon MJ, et al. 2005b. Vascular and metabolic effect of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension, 45:1088-93.
38. Kullo IJ, Seward JB, Bailey KR, et al. 2005. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens, 18:1123-9.
39. Lassegue B, Clepmpus RE. 2003. NAD(P)H oxidase: specific features, expression and regulation. Am J Physiol Regul Integr Comp Physiol, 285:R277-R97.
40. Liu J, Yang F, Yang X-P, et al. 2003. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol, 23:776-82.
41. Liuzzo G, Blasucci LM, Gallimore JR, et al. 1994. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med, 331:417-24.
42. Miyazawa K, Kiyono S, Inoue K. 1989. Modulation of stimulus-dependent human platelet activation by C-reactive protein modified with active oxygen species. J Immunol, 141:570-4.
43. Niskanen L, Laaksonen DE, Nyyssonen K, et al. 2004. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension, 44:859-65.
44. Nissen SE, Tuzeu EM, Schoenhagen P, et al. 2005. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 352:29-38.
45. Obisesan TO, Leeuwemburgh C, Phillips T, et al. 2004. C-Reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels. Arterioscler Thromb Vasc Biol, 24:1874-9.
46. Palmas W, Ma S, Psaty B, et al. 2007. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens, 20:233-41.
47. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-Reactive protein on human endothelial cells. Circulation, 102:2165-8.
48. Pastore L, Tessitore A, Martinottti S, et al. 1999. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increase soluble ICAM-1 release in vivo. Circulation, 100:1646-52.
49. Pepys MB, Hirschfield GM. 2003. C-reactive protein: a critical update. J Clin Invest, 111:1805-12.
50. Potempa LA, Siegel NJ, Fiedel BA, et al. 1987. Expression, detection and assay of neoantigen (neo-CRP) associated with a free C-reactive protein subunit. Mol Immunol, 24:531-41.
51. Pueyo ME, Gonzalez W, Nicoletti A, et al. 2000. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol, 20:645-51.
52. Qamirani E, Ren Y, Kuo L, Hein W. 2005. C-reactive protein inhibits endothelin-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol, 25:995-1001.
53. Rajagopalan S, Brook R, Mehta RH, et al. 2002. Effect of losartan in aging related endothelial impairment. Am J Cardiol, 89:562-66.
54. Rajagopalan S, Kurz S, Munzel T, et al. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest, 97:1916-23.
55. Ridker PM, Buring JE, Shih J, et al. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 98:731-3.
56. Ridker PM, Cannon CP, Morrow D, et al. 2005. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 352:20-8.
57. Ridker PM, Cushman M, Stampfer MJ, et al. 1997. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 336:973-6.
58. Ridker PM, Danielson E, Rifai N, Glynn RJ. 2006. for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein. Primary report of the Val-MARC trial. Hypertension, 48:73-79.
59. Sardo MA, Castaldo M, Cinquegrani M, et al. 2004. Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive - patients. Angiology, 55:195-203.
60. Savoia C, Schiffrin EL. 2006. Inflammation in hypertension. Curr Opin Nephrol Hypertens, 2:152-8.
61. Savoia C, Schiffrin EL. 2007. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond), 112:375-84.
62. Schieffer B, Bunter C, Witte J, et al. 2004. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol, 44:362-8.
63. Schieffer B, Luchtefeld M, Braun S, et al. 2000. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res, 87:1195-201.
64. Schiffrin EL, Touyz RM. 2003a. Inflammation and vascular hypertrophy induced by angiotensin II: role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation? Arterioscler Thromb Vasc Biol, 23:707-9.
65. Schiffrin EL, Touyz RM. 2003b. Multiple actions of angiotensin II in hypertension: benefits of AT, receptor blockade. J Am Coll Cardiol, 42:911-13.
66. Schiffrin EL, Touyz RM. 2004. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol, 287: H435-H-46.
67. Sesso HD, Buring JE, Rifai N, et al. 2003. C-reactive protein and the risk of developing hypertension. J Am Med Assoc, 290:2945-51.
68. Smith GD, Lawlor DA, Harbord R, et al. 2005. Association of C-reactive protein with blood pressure and hypertension. Life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol, 25:1051-6.
69. Strandberg TE, Vanhanen H, Tikkanen MJ. 1999. Effects of statins on C-reactive protein in patients with coronary artery disease. Lancet, 353:118-19.
70. Takeda T, Oshida S, Nishino M, et al. 2003. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive protein levels. Atherosclerosis, 169:155-8.
71. Taylor KE, Giddings JC, van den Berg CW. 2005. C-reactive protein-induced in vitro endothelial cell activation is an artifact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol, 25:1225-30.
72. Thorand B, Lowel H, Schneider A, et al. 2003. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med, 163:93-9.
73. Torzewski M, Rist C, Mortensen RF, et al. 2000. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol, 20:2094-9.
74. Touyz RM, Chen X, Tabet F, et al. 2002. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res, 90:1205-13.
75. Touyz RM, Savoia C, He Y, et al. 2007. Increased inflammatory biomarkers in hypertensive type2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. J Am Soc Hypertens (JASH), in press:
76. Touyz RM, Schiffrin EL. 2000. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev, 52:639-72.
77. Touyz RM, Schiffrin EL. 2001. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens, 19:1245-54.
78. Touyz RM, Schiffrin EL. 2004. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol, 122:339-52.
79. Touyz RM, Tabet F, Schiffrin EL. 2003. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol, 30:860-6.
80. Vaughan DE, Lazos SA, Tong K. 1995. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest, 95:995-1001.
81. Venugopal SK, Devaraj S, Jialal I. 2005. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol, 166:1265-71.
82. Venugopal SH, Devaraj S, Yuhanna I, et al. 2002. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation, 106:1439-41.
83. Verma S, Li SH, Badiwala MV, et al. 2002. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effect of C-reactive protein. Circulation, 105:1890-6.
84. Vigo C. 1985. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J Biol Chem, 260:3418-22.
85. Vongpatanasin W, Thomas GD, Schwartz L, et al. 2007. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation, 115:1020-8.
86. Wang CH, Li SH, Weisel RD, et al. 2003. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation, 107:1783-90.
87. Whitworth JA, Chalmers J. 2004. World health organisation-international society of hypertension (WHO/ISH) hypertension guidelines. Clin Exp Hypertens, 26:747-52.
88. Yasojima K, Schwab C, McGeer EG, McGeer PL. 2001. Generation of C-reactive protein and complement components in atherosclerothic plaques. Am J Pathol, 158:1039-51.
89. Yasunari K, Maeda K, Watanabe T, et al. 2004. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol, 43:2116-23.
90. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role of cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol, 19:972-8.
91. Zouki C, Beauchamp M, Baron C, et al. 1997. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest, 100:522-9.
92. Zouki C, Haas B, Chan JSD, et al. 2001. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol, 167:5355-61.
93. Zwaka TP, Hombach V, Torzewski J. 2001. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation, 103:1194-7.